Condition: HIV-1-infection · Sponsor: Gilead Sciences
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events. The primary objectives of this study are as follows: * To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment. * To evaluate the safety of the study drug(s) in participants with HIV-1.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| Helios Salud | Buenos Aires, Argentina | Active Not Recruiting |
| Hospital del Niño | Panama City, Panama | Active Not Recruiting |
| University of Stellenbosch | Cape Town, South Africa | Recruiting |
| Enhancing Care Foundation | Durban, South Africa | Recruiting |
| WITS RHI Research Centre | Johannesburg, South Africa | Recruiting |
| Rahima Moosa Mother and Child Hospital | Johannesburg, South Africa | Recruiting |
| Be Part Yoluntu Centre | Paarl, South Africa | Recruiting |
| The Aurun Institute | Pretoria, South Africa | Recruiting |
| Perinatal HIV Research Unit | Soweto, South Africa | Recruiting |
| Faculty of Medicine - Mahidol University | Bangkok Noi, Thailand | Active Not Recruiting |
| Khon Kaen University | Khon Kaen, Thailand | Active Not Recruiting |
| Joint Clinical Research Centre | Kampala, Uganda | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06337032